UACC-893 (ATCC® CRL-1902)

Organism: Homo sapiens, human  /  Tissue: mammary gland; breast  /  Disease: primary ductal carcinoma

Permits and Restrictions

View Permits View Restrictions

Organism Homo sapiens, human
Tissue mammary gland; breast
Product Format frozen
Morphology epithelial
Culture Properties adherent
Biosafety Level 1

Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country.

Disease primary ductal carcinoma
Age 57 years
Gender female
Ethnicity Caucasian
Storage Conditions liquid nitrogen vapor temperature
Karyotype modal number = 62; range = 51 to 65
This cell line was established by A. Liebovitz and associates in 1987 from breast tissue removed at lumpectomy to remove a ductal carcinoma (stage II).­
Clinical Data
57 years
Prior to surgery, the patient had received no chemotherapy.

The cells exhibit a 20 fold amplification of the HER-2/neu oncogene sequence. 

The cells grow very slowly, and growth can be enhanced by using 20% fetal bovine serum and adding epidermal growth factor (10 ng/mL) to the medium. 

They are negative for estrogen receptors, progesterone receptors and P glycoprotein.

Complete Growth Medium The base medium for this cell line is ATCC-formulated Leibovitz's L-15 Medium, Catalog No. 30-2008. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%.

(Note: The L-15 medium formulation was devised for use in a free gas exchange with atmospheric air. A CO2 and air mixture is detrimental to cells when using this medium for cultivation)

Volumes are given for a 75 cm2 flask. Increase or decrease the amount of dissociation medium needed proportionally for culture vessels of other sizes.
  1. Remove and discard culture medium.
  2. Briefly rinse the cell layer with 0.25% (w/v) Trypsin - 0.53 mM EDTA solution to remove all traces of serum which contains trypsin inhibitor.
  3. Add 2.0 to 3.0 mL of Trypsin-EDTA solution to flask and observe cells under an inverted microscope until cell layer is dispersed (usually within 5 to 15 minutes).
    Note: To avoid clumping do not agitate the cells by hitting or shaking the flask while waiting for the cells to detach. Cells that are difficult to detach may be placed at 37°C to facilitate dispersal.
  4. Add 6.0 to 8.0 mL of complete growth medium and aspirate cells by gently pipetting.
  5. Add appropriate aliquots of the cell suspension to new culture vessels.
  6. Incubate cultures at 37°C.
Subcultivation Ratio: A subcultivation ratio of 1:2 to 1:3 is recommended
Medium Renewal: Every 2 to 3 days
Freeze medium: Complete growth medium, 95%; DMSO, 5%
Storage temperature: liquid nitrogen vapor temperature
Culture Conditions
Atmosphere: air, 100%
Temperature: 37°C
STR Profile
Amelogenin: X
CSF1PO: 11,12
D13S317: 13
D16S539: 9,13
D5S818: 12
D7S820: 11
THO1: 6,9.3
vWA: 16,17
Population Doubling Time 100 hrs
Name of Depositor A Liebovitz, J Trent
Year of Origin 1987

Proc. Am. Assoc. Cancer Res. 29: 24, 1988.

Li J, et al. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 275: 1943-1947, 1997. PubMed: 9072974

Notice: Necessary PermitsPermits

These permits may be required for shipping this product:

  • Customers located in the state of Hawaii will need to contact the Hawaii Department of Agriculture to determine if an Import Permit is required. A copy of the permit or documentation that a permit is not required must be sent to ATCC in advance of shipment.
Basic Documentation

The breast carcinoma UACC-893 was deposited in the ATCC by Albert Leibovitz and Jeffrey M. Trent, Arizona Cancer Center, University of Arizona, Tucson, Arizona.These cells are distributed for research purposes only. The University of Arizona releases the line subject to the following: 1. UACC-893 cells or their products must not be distributed to third parties. Commercial interests are the exclusive property of the University of Arizona; 2. Any proposed commercial use of these cells must first be negotiated with The Director of The Arizona Cancer Center, University of Arizona, 1501 N. Campbell Ave., Tucson, AZ 85724. Telephone (602) 626-7925, FAX (602) 626-2284; 3. In all papers reporting any use of these cells or derived products, a direct reference will be made to the original publications (Proc. Am. Assoc. Cancer Res. 29: 24, 1988; Br. J. Cancer 63: 727-735, 1991).


Proc. Am. Assoc. Cancer Res. 29: 24, 1988.

Li J, et al. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 275: 1943-1947, 1997. PubMed: 9072974